Your browser doesn't support javascript.
loading
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer, Mark B; Rivière, Isabelle; Sénéchal, Brigitte; Wang, Xiuyan; Wang, Yongzeng; Purdon, Terence J; Hsu, Meier; Devlin, Sean M; Halton, Elizabeth; Lamanna, Nicole; Rademaker, Jurgen; Sadelain, Michel; Brentjens, Renier J; Park, Jae H.
Afiliación
  • Geyer MB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rivière I; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sénéchal B; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wang X; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wang Y; Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Purdon TJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hsu M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Devlin SM; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Halton E; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lamanna N; Department of Medicine, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA.
  • Rademaker J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sadelain M; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Brentjens RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: brentjer@mskcc.org
  • Park JH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mol Ther ; 26(8): 1896-1905, 2018 08 01.
Article en En | MEDLINE | ID: mdl-29910179
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T / Leucemia Linfocítica Crónica de Células B / Inmunoterapia Adoptiva / Antígenos CD19 / Ciclofosfamida Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T / Leucemia Linfocítica Crónica de Células B / Inmunoterapia Adoptiva / Antígenos CD19 / Ciclofosfamida Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos